Multiple myeloma therapies

Nature Reviews Drug Discovery

Volumn 6, Issue 3, 2007, Pages 181-182

  Strobeck, Matthew ^a  

^a One Financial Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINOGELDANAMYCIN; 3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CD40 ANTIGEN; CNF 1010; CNF 2024; DENOSUMAB; DEXAMETHASONE; FLUPHENAZINE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IPI 504; KOS 953; LENALIDOMIDE; MELPHALAN; OSTEOCLAST DIFFERENTIATION FACTOR; PERIFOSINE; PR 171; PREDNISONE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN SERINE THREONINE KINASE; SEROTONIN; SGN 40; THALIDOMIDE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GENE TARGETING; HUMAN; MONOTHERAPY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZOQUINONES; BORONIC ACIDS; CLINICAL TRIALS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LACTAMS, MACROCYCLIC; MELPHALAN; MULTIPLE MYELOMA; PYRAZINES; THALIDOMIDE;

EID: 33847349339     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2269     Document Type: Article

References (11)

1. Richardson, P. New treatments for myeloma. Oncology 14, 1781-1992 (2005).
2. Richardson, P. G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487-2498 (2005).
3. Mateos, M. V. et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study. Blood 108, 2165-2172 (2006).
4. Rajkumar, S. V. et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 24, 431-436 (2006).
5. Facon, T. et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J. Clin. Oncol. 24 (Suppl. 18), Abstract 1 (2006).
6. Weber, D. et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of 2 Phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. Blood108 (ASH Annual Meeting Abstracts), Abstract 3547 (2006).
7. Palumbo, A. et al. Oral revlimid plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: Results of a multicenter Phase I/ II study. Blood 108 (ASH Annual Meeting Abstracts), Abstract 800 (2006).
8. Mitsiades, C. S. et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 107,1092-1100 (2006).
9. Schey, S. A. et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol. 22, 3269-3276 (2004).
10. Hideshima, T. et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits AKT and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107, 4053-4062 (2006).
11. Silvestris, F. Myeloma bone disease: Pathogenetic mechanisms and clinical assessment. Leuk. Res. 30, 1016-1020 (2006).